Compounds > actinium
Page last updated: 2024-08-22

actinium and Breast Neoplasms

actinium has been researched along with Breast Neoplasms in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (12.50)29.6817
2010's4 (50.00)24.3611
2020's3 (37.50)2.80

Authors

AuthorsStudies
Bruchertseifer, F; Denkova, AG; Heskamp, S; Kip, A; Kruijff, RM; Molkenboer-Kuenen, J; Morgenstern, A; Raavé, R1
Ji, NT; Karimian, A; Sgouros, G; Song, H1
Bilewicz, A; Bouziotis, P; Bruchertseifer, F; Cędrowska, E; Gawęda, W; Karageorgou, MA; Krysiński, P; Morgenstern, A; Pruszyński, M; Żuk, M1
Abergel, RJ; Agbo, P; An, DD; Gauny, SS; Liu, X; Minor, AM; Pallares, RM; Zeltmann, SE1
Akudugu, JM; Domogauer, JD; Howell, RW; Khullar, A; Pasternack, JB1
Bruchertseifer, F; Huso, DL; Jin, K; Liangfeng, H; Morgenstern, A; Park, S; Sgouros, G; Song, H; Sukumar, S; Yoshida, T; Zhang, Z; Zhu, C1
Bruchertseifer, F; Kevrekidis, IG; Menzenski, MZ; Morgenstern, A; Sempkowski, M; Sofou, S; Zhu, C1
Ballangrud, AM; Borchardt, PE; Enmon, R; McDevitt, MR; Palm, S; Pellegrini, VA; Scheinberg, DA; Sgouros, G; Yang, WH1

Other Studies

8 other study(ies) available for actinium and Breast Neoplasms

ArticleYear
The in vivo fate of
    Scientific reports, 2019, 08-12, Volume: 9, Issue:1

    Topics: Actinium; Alpha Particles; Animals; Breast Neoplasms; Cell Line, Tumor; Chelating Agents; Drug Carriers; Female; Heterocyclic Compounds, 1-Ring; Humans; Injections, Intralesional; Injections, Subcutaneous; Mice; Mice, Inbred BALB C; Radiopharmaceuticals; Survival Analysis; Tumor Burden

2019
Mathematical Modeling of Preclinical Alpha-Emitter Radiopharmaceutical Therapy.
    Cancer research, 2020, 02-15, Volume: 80, Issue:4

    Topics: Actinium; Alpha Particles; Animals; Antibodies, Monoclonal; Bismuth; Breast Neoplasms; Cell Line, Tumor; Diffusion Magnetic Resonance Imaging; Disease Management; Dose Fractionation, Radiation; Drug Administration Schedule; Female; Humans; Image Processing, Computer-Assisted; Mice; Mice, Transgenic; Models, Biological; Positron-Emission Tomography; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Single Photon Emission Computed Tomography Computed Tomography

2020
Trastuzumab Conjugated Superparamagnetic Iron Oxide Nanoparticles Labeled with
    Molecules (Basel, Switzerland), 2020, Feb-25, Volume: 25, Issue:5

    Topics: Actinium; Ado-Trastuzumab Emtansine; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Female; Ferric Compounds; Humans; Hyperthermia, Induced; Magnetics; Magnetite Nanoparticles; Radioimmunotherapy; Receptor, ErbB-2

2020
Engineering Mesoporous Silica Nanoparticles for Targeted Alpha Therapy against Breast Cancer.
    ACS applied materials & interfaces, 2020, Sep-09, Volume: 12, Issue:36

    Topics: Actinium; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Female; Heterocyclic Compounds, 1-Ring; Humans; Molecular Structure; Nanoparticles; Optical Imaging; Particle Size; Porosity; Pyridones; Silicon Dioxide; Surface Properties; Transferrin

2020
The advantage of antibody cocktails for targeted alpha therapy depends on specific activity.
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2014, Volume: 55, Issue:12

    Topics: Actinium; Algorithms; Alpha Particles; Antibodies; Astatine; Bismuth; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Drug Combinations; Female; Humans; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals

2014
Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
    Oncotarget, 2016, May-31, Volume: 7, Issue:22

    Topics: Actinium; Alpha Particles; Animals; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltrating; Female; Humans; Immunoconjugates; MCF-7 Cells; Mice, Inbred NOD; Radioimmunotherapy; Radioisotopes; Radiopharmaceuticals; Receptor, ErbB-2; Tissue Distribution; Trastuzumab; Tumor Burden; Xenograft Model Antitumor Assays

2016
Sticky Patches on Lipid Nanoparticles Enable the Selective Targeting and Killing of Untargetable Cancer Cells.
    Langmuir : the ACS journal of surfaces and colloids, 2016, 08-23, Volume: 32, Issue:33

    Topics: Actinium; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Doxorubicin; Drug Delivery Systems; Endocytosis; Female; Humans; Kinetics; Ligands; Lipids; MCF-7 Cells; Nanoparticles; Nanotechnology; Receptor, ErbB-2

2016
Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2004, Jul-01, Volume: 10, Issue:13

    Topics: Actinium; Alpha Particles; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Radiation; Enzyme Multiplied Immunoassay Technique; Flow Cytometry; Humans; Microscopy, Confocal; Radioimmunotherapy; Receptor, ErbB-2; Time Factors; Trastuzumab

2004